Forgot Password?
Return to Course Listing

CME: Integrating novel PrEP options as a step toward ending the HIV epidemic

Activity Description / Statement of Need:

In this online, self-learning activity:

According to the Centers for Disease Control and Prevention (CDC), there are nearly 1.2 million people aged 13 years and older living with HIV (PLWH) in the U.S. Since the beginning of the HIV epidemic in the 1980s, advances in public health initiatives and treatments have considerably lengthened the life expectancy of PLWH, while simultaneously reducing transmission and diagnosis of new cases. Nonetheless, an estimated 31,000 people are infected with HIV each year in the United States, with the highest incidence in people from underserved and marginalized communities. As a result, a key component of the federal Ending the HIV Epidemic (EHE) strategy is to prevent new HIV infections by expanding use of evidence-based interventions.

Target Audience:

HCPs including: Infectious disease specialists, primary care physicians, and public health professionals; physician assistants, nurse practitioners, and pharmacists who practice in infectious disease; and any other HCPs with an interest in or who clinically encounter HIV. 

Commercial Support Disclosure: This program is supported by an educational grant from Gilead.

This activity is free of charge.

Release Date: July 22, 2023 -- Expiration Date: July 22, 2024

Faculty: Connie Celum, MD, MPH


Introduction, disclosures 

Overview of HIV Prevention 

  • Brief primer on notable updates in HIV epidemiology 
  • New infections: highest-incidence populations 
  • Risk factors for HIV transmission 
  • Effect of COVID19 on HIV transmission 
  • HIV prevention options 
  • Pre-exposure prophylaxis (PrEP) 
  • Post-exposure prophylaxis 
  • Risk-reducing behaviors 
  • US Ending the HIV Epidemic strategy 
  • PrEP coverage targets 

Optimizing PrEP Delivery 

  • Guideline recommendations 
  • CDC 
  • FDA-approved PrEP options: comparison of dosing route and frequency, efficacy and safety, patient-reported outcomes (e.g., satisfaction), and real-world data 
  • Emtricitabine/tenofovir alafenamide 
  • Emtricitabine/tenofovir disoproxil fumarate 
  • Cabotegravir extended-release injectable suspension 
  • PrEP prescribing: best practices 
  • Identification of candidate patients 
  • Selection of PrEP regimen through shared decision making 
  • Monitoring and follow-up 
  • Patient eduction and counseling 
  • Increasing accessibility 
  • Improving and monitoring adherence 
  • Safety considerations for specific patient populations 
  • Renal impairment 
  • Pregnancy and breastfeeding 
  • Hepatitis B or C coinfections 
  • Looking to the future: advances in PrEP
  • Islatravir 
  • Lencapavir 
  • Technology 
  • Ingestible biosensors 
  • Vaccination 
  • Barriers to vaccine programs 
  • Recent high-profile trial results 
  • Ongoing clinical trials 

Patient case(s)

Summary, conclusions, and best practices review 

Learning Objectives

By the end of the session the participant will be able to:

  • Discuss the US recommendations for the use of pre-exposure prophylaxis (PrEP) to meet national goals for HIV transmission.
  • Analyze the data that support the safety and efficacy of PrEP for the prevention of HIV infection in various populations and apply it to patient cases.
  • Describe efficacy, safety, and patient-reported outcomes data associated with novel and emerging long-acting PrEP options and other innovations in PrEP technology.
  • Implement strategies for overcoming barriers to PrEP use, including adherence-related challenges.


ACCME Activity #202540668

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through ScientiaCME. ScientiaCME is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation: ScientiaCME designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ toward the AMA Physician's Recognition Award. Physicians should only claim credit commensurate with the extent of their participation in the activity.


ABIM MOC Recognition Statement: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

ABIM MOC Credit Type: Medical Knowledge

Physicians: For maintenance of certification (MOC) points, you must enter your board certification ID # and birth date correctly.  It is the learner's responsibility to provide this information completely and accurately at the completion of the activity. Without providing it, the learner will NOT receive MOC points for this activity. By providing this data, you acknowledge that it will be shared with ACCME and the applicable certifying board. Please note: Not all activities on this site provide MOC points. If this activity does not specify that it provides MOC points in this section, then it does NOT provide MOC points. This activity provides MOC points only for ABIM.


ScientiaCME is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours (0.1 CEUs) of continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit. ACPE #0574-0000-23-028-H02-P. This is an Application (A)-type activity. 

PharmacistsYou must enter your NABP # and birth date correctly so that proof of participation can be posted to your NABP CPE profile. It is the learner's responsibility to provide this information completely and accurately at the completion of the activity. Without providing it, the learner will NOT receive CPE credit for this activity.

Nurses: The American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. This activity is designated for up to 1.0 AMA PRA Category 1 Credit(s)™.

Physician Assistants: The American Academy of Physician Assistants (AAPA) accepts AMA PRA Category 1 Credit™ assigned by organizations accredited by the ACCME as satisfying Category 1 CME for National Commission on Certification of Physician Assistants (NCCPA) national certification maintenance. This activity is designated for up to 1.0 AMA PRA Category 1 Credit(s)™.

Nurse Practitioners: The American Academy of Nurse Practitioners Certification Board (AANPCB) states that continuing education providers accredited by the ACCME may provide acceptable, accredited Advanced Practice Provider content. This activity is designated for up to 1.0 AMA PRA Category 1 Credit(s)™.

Faculty Disclosure and Resolution of COI

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.

Disclosures of Faculty: Connie Celum, MD, MPH, Professor of Global Health & Medicine, Director, Centerfor AIDS Research, University of Washington, has received financial compensation from Gilead and Merck for consulting work and Gilead for serving as an expert witness.

Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.

Faculty WILL NOT discuss off-label uses of a commercial product.

All relevant financial relationships have been mitigated.

ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Commercial Support Disclosure: This program is supported by an educational grant from Gilead.


  • Read the learning objectives above
  • Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
  • View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
  • Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
  • Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

System Requirements

Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh

*Required to view Printable PDF Version

Perform Pre-Test (optional)

Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.

Additional Courses That Are Related To This Activity

Addressing unmet needs and appreciating the place of vaccination in the prevention of human papillomavirus (HPV) infection

The changing landscape of acute COVID‑19 treatment

The difficulty with (C.) difficile: guideline updates and optimal identification and treatment strategies

Vaccine hesitancy and denial: A problem for the ages coming into sharp focus during the pandemic